Study identifier:NIS-RLA-XXX-2011/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Prevalence study and regular practice (diagnosis and treatment) among general practitioners in populations at risk of COPD in Latin America
Chronic Obstructive Pulmonary Disease
-
No
-
All
1907
Observational
40 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Apr 2013 by AstraZeneca
AstraZeneca
-
PUMA is an observational, multicentre, multinational, cross-sectional study with primary care physicians (primary care, general and family physicians). Participants will be selected sequentially among patients at risk for Chronic Obstructive Pulmonary Disease (COPD) who attend primary care consultation (primary care, general and family physicians). The inclusion visit will be a regularly scheduled or spontaneous consultation for patients, and this appointment with the physician will not depend on the study. During the appointment, data will be collected from the patient and the physician.
PREVALENCE STUDY AND REGULAR PRACTICE (DIAGNOSIS AND TREATMENT) AMONG GENERAL PRACTICIONERS IN POPULATIONS AT RISK OF COPD IN LATIN AMERICA
Location
Location
Caracas, Venezuela
Location
Maracaibo, Venezuela
Location
Porlamar, Venezuela
Location
Valencia, Venezuela
Location
Barquisimeto, Venezuela
Location
CAPITAL FEDERAL, CAPITAL FEDERAL, Argentina
Location
QUILMES, Buenos Aires, Argentina
Location
EZEIZA, Buenos Aires, Argentina
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.